VESTIBULAR VERTIGO. EXPERIENCE IN USING BETAVER

Abstract

The authors studied the causes of vestibular vertigo was studied in 40 patients (9 men and 31 women aged 29 to 83 years, mean age 58,6 years) admitted to the Neurology Department for this condition and the efficiency of betaver (betahistine) used for treatment. The causes of isolated vestibular vertigo in the patients were benign paroxysmal positional vertigo (n = 21), Meniere's syndrome or peripheral vestibulopathy (n = 9), Meniere's disease (n = 5), vestibular neuronitis (n = 4), and vestibular migraine (n = 1). All the examinees took betaver in a dose of 48 mg/day for 30 days. Betaver treatment resulted in cessation of vertigo in all the patients during their hospital stay (15-25 days, mean 21 days). Improvement could be also associated with natural vertigo regression and with the benefits from the rehabilitation maneuver (in benign paroxysmal positional vertigo) made by the patients under advice of a vestibular exercise physician. It was noted that betaver interacted well with other drugs taken by the patients for concomitant disease and there were no changes in clinical and biochemical blood indices.